SmartKem, Inc.

What they do

SmartKem was incorporated in 2009 and develops organic semiconductor materials and related processes for thin-film transistor applications. The company describes its core offering as TRUFLEX materials and states it has not generated revenue from commercial sales to date, instead incurring losses while conducting research and development and building manufacturing, sales, marketing and distribution capabilities. It relies on third-party supply, manufacturing and fabrication partners rather than owning its own fabs.

Revenue drivers

• TRUFLEX materials — The company's core organic semiconductor material platform; management states in the 10-K risk factors that it has generated no revenue from commercial sales to date, so this line is not yet contributing commercial revenue.
• Collaboration, license and royalty arrangements — The filings list receipt and timing of royalties, milestone payments or payments for products under current or future collaboration, license or other agreements as a forward-looking item, but no specific agreement amounts are disclosed in the excerpts provided.
• Reported revenue (pre-commercial) — XBRL annual revenue was $18,000 in 2021, $40,000 in 2022, $27,000 in 2023, $82,000 in 2024 and $697,000 in 2025; the 2025 total is the largest reported to date and is far below annual operating cash use of roughly $7.7M-$9.7M per year.
• Quarterly revenue pattern — Recent quarterly revenue was $32,000 (2025-06-30), $81,000 (2025-09-30), $561,000 (2025-12-31) and $20,000 (2026-03-31), indicating revenue is lumpy and concentrated in individual periods.

Recent performance

Annual revenue rose from $82,000 in 2024 to $697,000 in 2025, but net loss was $10.5 million in 2025 versus $10.3 million in 2024, and operating cash flow was negative $7.7 million in 2025. The 10-K risk factors state comprehensive losses of $13.0 million for 2025 and $9.9 million for 2024 and an accumulated deficit of $125.1 million as of December 31, 2025. Quarterly revenue fell to $20,000 in the quarter ended 2026-03-31 after $561,000 in the quarter ended 2025-12-31. The latest balance sheet shows total assets of $10.4 million, total liabilities of $675,000, shareholder equity of $9.7 million and cash and equivalents of $3.7 million as of 2026-06-30.

Strategy

Management states it is continuing research and development on its TRUFLEX materials while developing manufacturing, sales, marketing and distribution capabilities, and expects to operate at a net loss for at least the next several years. The company relies on third-party supply, manufacturing and fabrication partners, which it identifies as a dependency in its forward-looking statements. The 10-K risk factors indicate the company believes it will need to raise substantial additional capital to fund operations and commercialization. The excerpts provided do not disclose specific product launch timelines, customer names or contract values.

Risks

• Going concern — The 10-K risk factors state that recurring losses have raised substantial doubt about the ability to continue as a going concern, with an accumulated deficit of $125.1 million as of December 31, 2025.
• No commercial revenue — Management states the company has generated no revenue from commercial sales to date, and annual revenue has never exceeded $697,000 against annual operating cash use of roughly $7.7M-$9.7M over 2021-2025.
• Nasdaq listing compliance — A delisting notice or listing-rule failure was reported on 2026-09-14, and both the 10-K and 10-Q list maintaining Nasdaq continued listing compliance as a forward-looking risk.
• Dilution from financings — The 10-K states the company will need to raise substantial additional capital, and recent 8-K events on 2026-06-26, 2026-07-21 and 2026-07-27 report entry into material agreements and unregistered sales of equity.

Outlook

Management states it expects operating losses to continue for the foreseeable future due to research funding and further development of its technology and products, and that it believes it will need to raise substantial additional capital. No revenue guidance, product launch dates or named customer commitments are provided in the excerpts. The company also flags maintaining Nasdaq listing compliance and, if delisted, remaining eligible on an over-the-counter quotation system as open items.